TG Therapeutics (TGTX)

• Market cap: $4.89B
• 1 day: -1.97%
• 5 days: 1.35%
• 1 month: 0.33%
• 3 months: -3.75%
• 6 months: -13.58%
• Year to date: -0.87%
• 1 year: -10.49%
• 5 years: -42.24%
• 10 years: 172.24%
• Sector: Healthcare
• Industry: Biotechnology

About: TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Employees: 352